NCT06205290 2024-04-02A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 3 Withdrawn